Misteltherapie bei Krebs: im Tiermodell gelang es nun
erstmalig auf molekularer Ebene im Fall einer lymphoblastischen
Leukämie die Wirksamkeit der Therapie mit einem Mistelextrakt
nachzuweisen. An der Universitätsklinik Charite, Berlin,
konnte gezeigt werden, dass der programmierte Zelltod (Apoptosis)
dosisabhängig ist und durch den Mistelwirkstoff ausgelöst werden
kann.
Mehr Informationen
zum Thema Misteltherapie bei Krebs finden Sie auf
diesen Websites
hier

Die
vollständige englischsprachige Kurzversion dieser Studie (sog.
MEDLINE Abstract) finden Sie hier
Titel: Molecular mechanisms of mistletoe plant extract-induced
apoptosis in acute lymphoblastic leukemia in vivo and in vitro.
Journal: Cancer Lett. 2008 Jun 18; 264(2): 218-28.
Autor(en):
Seifert G, Jesse P, Laengler A, Reindl T, Lüth M, Lobitz S,
Henze G, Prokop A, Lode HN
Bezug: Department of Pediatric Oncology/Hematology, Otto-Heubner-Center
for Pediatric and Adolescent Medicine (OHC), Charité, Universitätsmedizin
Berlin, Germany.
Abstract:
Viscum album (Mistletoe) is one of the most widely used alternative
cancer therapies. Aqueous mistletoe extracts (MT) contain the
three mistletoe lectins I, II and III as one predominant
group of biologically active agents. Although MT is widely used,
there is a lack of scientifically sound preclinical and clinical
data. In this paper, we describe for the first time the in
vivo efficacy and mechanism of action of MT in lymphoblastic
leukemia.
For
this purpose, we first investigated both the cytotoxic effect
and the mechanism of action of two standardized aqueous MTs
(MT obtained from fir trees (MT-A); MT obtained from pine trees
(MT-P)) in a human acute lymphoblastic leukemia (ALL) cell
line (NALM-6). MT-A, MT-P and ML-I inhibited cell proliferation
as determined by Casy((R)) Count analysis at very low concentrations
with MT-P being the most cytotoxic extract.
DNA-fragmentation
assays indicated that dose-dependent induction of apoptosis
was the main mechanism of cell death. Finally, we evaluated
the efficacy of MT-A and MT-P in an in vivo SCID-model of pre-B
ALL (NALM-6).
Both
MTs significantly improved survival (up to 55.4 days)
at all tested concentrations in contrast to controls (34.6 days)
without side effects.
PubMed-ID: 18314258
ISSN: 0304-3835 (Print)
Erstellungsdatum: 06.05.2008